Spironolactone. II. Bioavailability

Clinical Pharmacology and Therapeutics

Volumn 19, Issue 2, 1976, Pages 170-176

  Karim, A ^a   Zagarella, J ^a   Hutsell, T C ^a   Chao, A ^a   Baltes, B J ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANRENONE; MACROGOL 400; SPIRONOLACTONE; DRUG; MACROGOL ESTER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG SYNTHESIS; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TABLET; CLINICAL TRIAL; ORAL DRUG ADMINISTRATION; PHARMACEUTICS; PHARMACOKINETICS; SERUM; THEORETICAL STUDY; URINE;

ADMINISTRATION, ORAL; ADULT; BIOLOGICAL AVAILABILITY; CANRENONE; HUMANS; MALE; SOLUBILITY; SOLUTIONS; SPIRONOLACTONE; TABLETS; TIME FACTORS;

EID: 0017295858     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt1976192170     Document Type: Article

References (12)